714 assets in Colorectal Cancer

Therapeutic assets addressing Colorectal Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Zongertinib Colorectal Cancer	Boehringer Ingelheim	P1/2	CC (40)
68ga-dfc413 Colorectal Cancer	Novartis Pharmaceuticals	P1	C (39)
[68ga]ga-oncofap administration Colorectal Cancer	Philogen S.p.A.	P1	C (39)
azd0022 Colorectal Cancer	AstraZeneca	P1	C (39)
bi 765049 Colorectal Cancer	Boehringer Ingelheim	P1	C (39)
Cd-Ga-102 Colorectal Cancer	Shanghai Changzheng Hospital	Early P1	C (39)
Cdx-585 Colorectal Cancer	Celldex Therapeutics	P1	C (39)
Cnsi-Fe Colorectal Cancer	Sichuan Enray Pharmaceutical Sciences Company	P1	C (39)
Colonyvaq-Crc Colorectal Cancer	Biogenea Pharmaceuticals Ltd.	Early P1	C (39)
Cue-102 Colorectal Cancer	Cue Biopharma	P1	C (39)
Darlifarnib Colorectal Cancer	Kura Oncology, Inc.	P1	C (39)
Fludeoxyglucose Colorectal Cancer	Peking University Cancer Hospital & Institute	P1	C (39)
Fmpv-1 Colorectal Cancer	Hubro Therapeutics AS	P1	C (39)
hnf4α srrna Colorectal Cancer	Shanghai Changzheng Hospital	Early P1	C (39)
Idelalisib Colorectal Cancer	Oslo University Hospital	P2	C (39)
kqb368 Colorectal Cancer	Kumquat Biosciences Inc.	P1	C (39)
lt-010391 Colorectal Cancer	Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.	P1	C (39)
Migoprotafib Colorectal Cancer	Genentech, Inc.	P1	C (39)
Neoantigen Dna Vaccine Colorectal Cancer	Centre Georges Francois Leclerc	P1	C (39)
okn4395 Colorectal Cancer	Epkin	P1	C (39)
Oxycodone Colorectal Cancer	Fudan University	P1	C (39)
pd-1 knockout engineered t cells Colorectal Cancer	Ruijin Hospital	P1	C (39)
pd1-til Colorectal Cancer	Ruijin Hospital	P1	C (39)
Recombinant Human Egf-Rp64K Colorectal Cancer	Roswell Park Cancer Institute	Early P1	C (39)
Rmc-5127 Colorectal Cancer	Revolution Medicines, Inc.	P1	C (39)
Tovorafenib Colorectal Cancer	Day One Biopharmaceuticals, Inc.	P2	C (39)
Xmab808 Colorectal Cancer	Xencor, Inc.	P1	C (39)
Msc-L Colorectal Cancer	Shanghai East Hospital	Early P1	C (38)
Rock2 Inhibitor Kd025 Colorectal Cancer	jianming xu	Early P1	C (38)
WD-01 CAR-T Colorectal Cancer	Wondercel Biotech (ShenZhen)	Early P1	C (38)
5P12-RANTES Colorectal Cancer	Orion Biotechnology Polska Sp. z o.o.	P1	C (37)
Azenosertib Colorectal Cancer	K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc	P1	C (37)
Divarasib Colorectal Cancer	Hoffmann-La Roche	P1	C (37)
pb101 Colorectal Cancer	Panolos Bioscience	P1	C (37)
Rph-030 Colorectal Cancer	R-Pharm	P1	C (37)
SY 5609 Colorectal Cancer	Hoffmann-La Roche	P1	C (37)
[111in]-fpi-2058 Colorectal Cancer	3B Pharmaceuticals GmbH	P1	C (36)
177lu-dfc413 Colorectal Cancer	Novartis Pharmaceuticals	P1	C (36)
[177Lu]Lu-A9-0631 Colorectal Cancer	Alpha-9 Oncology USA Inc.	P1	C (36)
[177lu]lu-nns309 Colorectal Cancer	Novartis Pharmaceuticals	P1	C (36)
[225Ac]Ac-A9-0642 Colorectal Cancer	Alpha-9 Oncology USA Inc.	P1	C (36)
[225]-fpi-2059 Colorectal Cancer	3B Pharmaceuticals GmbH	P1	C (36)
(3RS)-1-(6-(.ALPHA.-METHYLPOLY(OXYETHYLENE)AMINO)-6-OXOHEXYL)-2,5-DIOXOPYRROLIDIN-3-YL)-L-CYSTEINAMIDE, (20000 MW) Colorectal Cancer	Lumicell, Inc.	P1/2	C (36)
[68Ga]Ga-NNS309 Colorectal Cancer	Novartis Pharmaceuticals	P1	C (36)
68Ga-NNS309 Colorectal Cancer	Novartis Pharmaceuticals	P1	C (36)
68ga-nodaga-sna009 Colorectal Cancer	SmartNuclide Biopharma	Early P1	C (36)
Abbv-400 Colorectal Cancer	AbbVie	P1	C (36)
ad5.f35-hgucy2c-padre vaccine Colorectal Cancer	Thomas Jefferson University	P1	C (36)
agx101 Colorectal Cancer	Angiex, Inc.	P1	C (36)
ai-061 Colorectal Cancer	OncoC4, Inc.	P1	C (36)

Showing 501 to 550 of 714 assets

PreviousPage 11 of 15Next